Biofrontera (NASDAQ: BFRI) reported third-quarter 2026 net product revenue of $9.1 million, up 29.8% from $7.0 million a year earlier. The company recorded a net loss of $6.4 million, or $0.42 per share, compared with a $6.6 million loss, or $0.62 per share, in the prior-year quarter.
Gross margin rose to 74.4% from 70.7%. For the first nine months of 2026, net product revenue was $31.2 million, up 26.6%, while net loss narrowed to $11.8 million from $16.2 million.
- Third-quarter net product revenue was $9.07 million on the condensed consolidated statements of operations.
- FDA approved Ameluz PDT for superficial basal cell carcinoma on September 9, 2026.
- U.S. Customs and Border Protection ruled the redesigned RhodoLED XL-C lamp was not subject to the ITC exclusion order.
- Cash and cash equivalents were $3.2 million as of September 30, 2026, versus $6.4 million at December 31, 2025.
- Adjusted EBITDA, a non-GAAP measure, was negative $5.5 million, compared with negative $6.0 million a year earlier.
$BFRIW Hedge Fund Activity
We have seen 1 institutional investors add shares of $BFRIW stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 45,804 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,232
- UBS GROUP AG added 9,908 shares (+2897.1%) to their portfolio in Q3 2026, for an estimated $97
- BARD ASSOCIATES INC added 0 shares (+0.0%) to their portfolio in Q3 2026, for an estimated $0
- OSAIC HOLDINGS, INC. added 0 shares (+0.0%) to their portfolio in Q3 2026, for an estimated $0
- US BANCORP \DE\ added 0 shares (+0.0%) to their portfolio in Q3 2026, for an estimated $0
- CLEAR STREET GROUP INC. added 0 shares (+0.0%) to their portfolio in Q2 2026, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.